|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,632.00 GBX | -0.69% |
|
-0.30% | -8.40% |
| 31/07 | EU Approves AstraZeneca and Daiichi Sankyo's Datroway for First-Line Triple-Negative Breast Cancer | MT |
| 31/07 | Astrazeneca, Daiichi Sankyo's Breast Cancer Therapy Receives EU approval | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 26TCr | |||||
| 1,02400Cr | |||||
| 62TCr | |||||
| 44TCr | |||||
| 35TCr | |||||
| 21TCr |
- Stock Market
- Stocks
- AZN Stock
- Charts AstraZeneca PLC
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
